Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osimertinib + rosuvastatin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two medications: osimertinib (Tagrisso) and rosuvastatin (Crestor). Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for treating non-small cell lung cancer (NSCLC) with specific EGFR mutations. Rosuvastatin is a statin medication used to lower cholesterol levels. When co-administered, osimertinib has been shown to increase rosuvastatin exposure by approximately 35% due to osimertinib's inhibitory effect on breast cancer resistance protein (BCRP) transporter, of which rosuvastatin is a substrate.
- Brand names
- Tagrisso + Crestor
02
Targets
TNK2 (Activated Cdc42-associated kinase 1)EGFR T790M (Epidermal growth factor receptor T790M mutant)ABCG2 (Breast cancer resistance protein)ERBB3 (Erb-b2 receptor tyrosine kinase 3)BLK (B lymphoid tyrosine kinase)ERBB4 (Erb-b2 receptor tyrosine kinase 4)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on osimertinib + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osimertinib + rosuvastatin.